Aptabio to present results of Isuzinaxib Phase 2 study at The American Society of Nephrology (ASN)'s Kidney Week 2022

Aptabio's Isuzinaxib (APX-115) proves its effect on a key kidney function marker in a Phase 2 clinical study in patients with diabetes and chronic kidney...

Related Keywords

United States ,South Korea ,Greece ,American ,Korea ,Greek ,Prnewswire Aptabio ,Hyesung Shin ,Dae Ryong Cha ,Centers For Disease ,Korea University College Of Medicine ,Human Services ,Drug Development Company ,Platform Technology ,Aptabio Therapeutics Inc ,American Society Of Nephrology ,Us Department Of Health ,Urine Albumin Creatine Ratio ,Isuzinaxib Phase ,American Society ,Kidney Week ,High Impact Clinical Trials ,Patients With Type ,Double Blind ,Placebo Controlled Phase ,Kidney Disease ,Kidney Injury ,Korea University College ,Aptabio Therapeutics ,Reactive Oxygen Species ,Diabetic Kidney ,Assess Safety ,Renal Effects ,Disease Control ,Chronic Kidney Disease ,